The Life Sciences team advised Tubulis on an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target with Gilead. Under the terms of the agreement, Tubulis will receive an upfront payment of $20 million and, if Gilead exercises its option, a separate option exercise fee of $30 million. In addition, Tubulis will be eligible for development and commercialization milestone payments totaling up to $415 million, plus mid-single to low double-digit tiered royalties on sales of marketed products resulting from the collaboration. Through this agreement, Gilead will gain access to Tubulis’ proprietary Tubutecan and Alco5 platforms.
Tubulis generates uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. The company’s first NaPi2b-targeting program, TUB-040, is being evaluated in the clinic in ovarian and non-small cell lung cancer. The second candidate from the growing pipeline, TUB-030, targeting 5T4, is set to follow imminently. The company’s goal is to expand the therapeutic potential of this drug class for the pipeline, partners and for patients.
The Goodwin team was led by Kingsley Taft and Alison Liou.
For more information on the deal, please read the press release and coverage in Endpoints News.